Zydus Cadila receives final approval for Diflunisal Tablets

Last Updated : Jun 20 2017 | 10:47 AM IST

From USFDA

Zydus Cadila has received final approval from USFDA to market Diflunisal Tablets in the strengths of 500 mg. It is a nonsteroidal anti-inflammatory drug (NSAID) and will be produced at the group's formulations manufacturing facility at Baddi.

Powered by Capital Market - Live News

Connect with us on WhatsApp

Zydus Cadila receives final approval for Felbamate Tablets

Zydus Cadila receives final approval for Eletriptan Hydrobromide Tablets

Zydus Cadila receives final approval for Cyproheptadine Hydrochloride Tablets USP

Zydus receives final approval for Olmesartan Medoxomil Tablets

Zydus Cadila receives final approval for Acyclovir for Injection USP

First Published: Jun 20 2017 | 10:30 AM IST

Explore News

Market LIVE
Parliament Winter Session 2024 LIVE
Latest News LIVE
Market Today
Stocks To Watch Today
Mobikwik IPO listing
IGI IPO Allotment
IND vs AUS 3rd Test Day 5 LIVE
IPO News
Business Standard at 50